Precision Solutions

• 
  Insect Cell / Baculovirus Protein Expression Service — Publication-Cited BEVS Platform

  AtaGenix's BEVS platform (Sf9/Sf21/Hi5) delivers properly folded, glycosylated recombinant proteins from milligram to gram scale. Four peer-reviewed publications showcase BEVS-produced reagents in oncology (Nat Commun, POLD1-MYC), tumor immunology (Biomed Pharmacother, PADI4 mAb), neuroscience (Nat Commun, PCIF1-MTase), and gynecological oncology (AJCR, ENO1 mAb). ISO 9001 & ISO 13485 certified.

• 
  Prokaryotic Protein Expression (E. coli) — 3H Platform with >95% Success Rate

  AtaGenix's 3H E. coli expression platform (>95% success rate) delivers publication-grade recombinant proteins from mg to gram scale. Optimized vectors (pET/pGEX), specialized strains (T7E, C41, Arctic), and full QC (purity ≥85%, endotoxin <0.1 EU/mL). Three peer-reviewed case studies — all in Nature Communications — showcase E. coli-expressed reagents for rice genetics (SDR3.1), Bt resistance (FTZ-F1), and cyanobacterial stress tolerance (shikimate kinase).

• 
  Mammalian Cell Protein Expression — HEK293 & CHO Platform, 5,000+ Projects Delivered

  AtaGenix's mammalian expression platform (HEK293/CHO-S transient, CHO-K1/DG44 stable) has delivered 5,000+ projects with 200+ stable cell lines. Four peer-reviewed publications showcase mammalian-expressed reagents: OMV tumor vaccine (Adv Mater IF 27.4), SARS-CoV-2 nanovaccine (Nat Commun IF 14.7), EAE neuroinflammation (Immunity IF 25.5), and PND complement inhibition (Mol Psychiatry IF 9.6). Class 100,000 cleanroom, endotoxin <0.1 EU/mL, ISO certified.

• 
  AtaGenix MOG Protein Enables Discovery of Meningeal B-Cell Mechanism in MS Relapse

  Using high-purity recombinant mouse MOG protein from AtaGenix, researchers established an EAE model and revealed how meningeal B cells drive MS relapse via MHC II-mediated antigen presentation, GM-CSF–dependent neutrophil recruitment, and endothelial activation. Local intracisternal anti-CD20 selectively depleted brain-resident B cells and reduced relapse severity. Published in Immunity (IF: 25.5). DOI: 10.1016/j.immuni.2025.06.016.

• 
  Rational Design of Patatin Lipase: 3.2× Long-Chain Fatty Acid Specificity via D286A Mutation

  Patatin is a potato glycoprotein with emulsifying and antioxidant properties but limited by low expression and short-chain bias. With AtaGenix support, recombinant Patatin was expressed in Pichia pastoris (121 mg/L). The D286A mutant showed 3.2-fold enhanced activity toward long-chain pNP-C16, improved thermal stability, and maintained overall fold — demonstrating the first rational shift of Patatin's substrate preference toward industrial applications in functional lipids and green biocatalysis.

• 
  Mammalian Cell Protein Expression Services — HEK293 & CHO Platform

  AtaGenix provides mammalian cell protein expression services (HEK293/CHO-S transient, CHO-K1/DG44 stable) for basic research, drug development, and diagnostic reagent production. 5,000+ projects delivered with native glycosylation, endotoxin <0.1 EU/mL, scalable from mL to 200 L+. ISO 9001 & ISO 13485 certified.

• 
  XtenCHO™ High-Density Transient Transfection Expression System

  XtenCHO™ is AtaGenix's proprietary high-density transient CHO expression system, achieving 200–400 mg/L typical yield (up to 1 g/L for select antibodies). Extended cell viability (10–14 days), cost-optimized reagents, and simplified workflows make it ideal for high-throughput antibody screening and scalable protein production. End-to-end from gene synthesis to bioreactor scale-up in 6–9 weeks.

• 
  Prokaryotic Protein Expression Services — E. coli 3H Platform

  AtaGenix's 3H E. coli expression platform delivers >95% success rate with optimized pET/pGEX vectors, specialized host strains (T7E, C41, Arctic), and complete QC pipeline (purity ≥85%, endotoxin <0.1 EU/mL). Supports antigens, enzymes, fusion proteins, and antibody immunogens from mg to gram scale. Reagents cited in three Nature Communications papers. ISO 9001 & ISO 13485 certified.

• 
  ENO1 Monoclonal Antibody Development for Cervical Cancer Glycolysis Targeting

  AtaGenix expressed ENO1 protein via Sf9/BEVS and screened five hybridoma cell lines producing anti-ENO1 monoclonal antibodies. ENO1mAbs blocked plasminogen activation, inhibited glycolysis, and suppressed cervical cancer cell (SiHa/HeLa) invasion, proliferation, and colony formation — establishing the basis for FA-SS-PLGA nanoparticle-mediated targeted therapy. Published in American Journal of Cancer Research.